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Abstract
The p53 tumour suppressor is the most frequently mutated gene in human cancer. This transcription factor can be 
activated by diverse cellular stresses, including DNA damage and oncogene activation.  Through transcriptional 
induction of appropriate target genes, p53 can stimulate activity in a broad range of effector pathways, most 
notably cell cycle arrest, cellular senescence and apoptotic cell death. Insensitivity to cell death-inducing signals 
and deregulated proliferation are two key hallmarks of cancer cells. Given that p53 inhibits proliferation and 
induces apoptosis, it was widely believed that these processes are the most critical ones for p53-mediated 
tumour suppression. However, this dogma has been challenged. In striking contrast to p53-deficient mice, which 
all develop tumours before 250 days of age, mutant mice in which expression of the p53 target genes that are 
critical for induction of cell cycle arrest and apoptosis is impaired or abrogated are not cancer-prone. This 
demonstrates that distinct effector processes are critical for the p53-mediated acute response to DNA damage 
versus p53-mediated tumour suppression. The discovery that cell cycle arrest, senescence and apoptosis are 
not essential for p53-mediated tumour suppression re-launches the search for the p53 target genes and effector 
processes that are critical to prevent tumour development, with coordination of DNA repair being a leading 
contender.
The role of p53 in the acute response to 
DNA damage
The transcription factor p53 is activated in response to a 
wide range of cellular stresses, including DNA damage 
(such as that induced by anti-cancer therapeutics), 
aberrant growth signals (e.g. as a consequence of 
oncogene activation), hypoxia, reactive oxygen species 
(ROS) and nucleotide depletion [1]. The role of p53 in 
the cellular response to acute DNA damage is particularly 
well characterised. Although p53 mRNA is expressed 
relatively constantly, under normal cellular conditions (i.e. 
in the absence of stress) p53 protein levels are generally 
very low; indeed in many cell types below the level of 
detection. This is mostly due to a negative feedback loop 
involving the E3-ubiquitin ligases, MDM2 and MDM4 [2-
4]. They inhibit inappropriate p53 activity by binding to 
its N-terminal transactivation domain thereby facilitating 
ubiquitination and consequent proteasomal degradation 
of p53 [5-7]. Additional proteins, such as HAUSP and 
DAXX, have also been implicated in regulating p53 
protein, either by deubiquiylating p53 (HAUSP) or by 
enhancing p53 ubiquitylation (DAXX) [8]. In response 
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to cellular stress p53 becomes stabilised and activated 
through a variety of mechanisms. While we will briefly 
discuss how this occurs in response to DNA damage, the 
post-translational modifications that stabilise and activate 
p53 have been discussed in greater detail by David Meek 
and colleagues in the last issue of BioDiscovery [9]. 
Maintenance of genomic integrity is critical for 
cell survival (and in the germline for propagation of 
the species). Cells have therefore evolved complex 
systems for the recognition and repair of DNA damage. 
Recognition of DNA lesions, such as double strand 
breaks (e.g. induced by γ-irradiation), replication stress 
induced by hyper-proliferation (particularly important in 
the context of cancer) or by stalling of replication forks 
during cell cycling, can lead to activation and recruitment 
of the kinases ATM, ATR, Chk1 and Chk2 to sites of 
damage. ATM and ATR are serine/threonine kinases 
that are directly activated in response to DNA damage 
and function to phosphorylate key substrates, including 
p53, MDM2 and the downstream kinases Chk1/Chk2 
[10-13]. Phosphorylation of p53 at serine 15, 20 and 
threonine 18 (all amino acid residues in human p53) 
is thought to activate p53 by enhancing its interaction 
with various members of the transcriptional machinery. 
This phosphorylation also inhibits degradation of p53 
by interfering with the p53-MDM2 interaction [10, 12, 
14-19]. Phosphorylation of MDM2 (on Serine 395) 
by ATM also further inhibits its interaction with p53 
[20, 21]. Moreover, ATM also indirectly promotes 
p53 accumulation through phosphorylation of Chk2, 
activating it to phosphorylate serine 20 on p53 (aa residue 
relates to human p53). This modification is believed 
to interfere with the p53-MDM2 interaction [22, 23]. 
Once stabilised, p53 can undergo a range of additional 
post-translational modifications, including acetylation, 
phosphorylation, neddylation and methylation, which 
are thought to influence the transcriptional activity 
of p53 [24]. p53 regulates gene transcription (either 
positively or negatively) by binding as a homo-tetramer 
in a sequence specific manner to the regulatory regions 
of ~600 target genes [24-26].  Transcriptional responses 
and effector pathways unleashed by p53 in response to 
DNA damage fall into three broad categories: (1) growth 
arrest, including cell cycle arrest and cellular senescence, 
(2) repair of damaged DNA and (3) removal of cells that 
have sustained irreparable genetic damage by apoptosis. 
Cell cycle arrest and cellular senescence
In response to DNA damage p53 can induce arrest of 
cellular proliferation. This can serve two functions: 
allowing cells time to repair their damaged DNA and 
blocking damaged cells from proliferating and thereby 
propagating aberrant DNA changes. This growth arrest 
can be transient or, in the case of cellular senescence, 
permanent. 
The best characterised mediator of p53-induced cell 
growth arrest is p21 (also called WAF1/CIP1). p21 was 
originally identified as a p53-responsive gene in a human 
glioblastoma cell carrying an inducible wild-type (wt) 
p53 expression construct [27]. Notably, over-expression 
of p21 was shown to suppress the growth of glioblastoma, 
lung adenocarcinoma and colon cancer derived cell lines 
in vitro. p21 binds directly to, and potently inhibits, 
the cyclin/CDK1 and cyclin/CDK2 cyclin dependent 
kinase complexes (CDKs). This blocks CDK-mediated 
phosphorylation of Rb, a process that is required for the 
release of the transcription factor, E2F, from Rb and thus 
progression from the G1 to the S phase of the cell cycle 
[28-31]. Mouse embryonic fibroblasts (MEF) lacking p21 
were found to be resistant to DNA damage-induced cell 
cycle arrest at the G1-S boundary. While γ-irradiated wt 
MEFs underwent G1-S boundary cell cycle arrest, p21-
deficient MEFs failed to arrest and consequently initiated 
replication of their damaged DNA [32]. Loss of p21 also 
promoted resistance to DNA damage-induced cell cycle 
arrest in vivo with comparable numbers of cells in S-phase 
observed in the gastrointestinal crypts of both γ-irradiated 
and untreated p21-/- mice whereas γ-irradiation caused a 
substantial reduction in cycling cells in wt mice [33]. 
Interestingly, p21 has also been suggested to function 
as an inhibitor of DNA damage induced cell death. Loss of 
p21 was shown to enhance the sensitivity of HCT116 colon 
cancer cells to daunomycin [34]. However, compared to 
wt MEFs, p21-/- MEFs treated with γ-irradiation did not 
exhibit enhanced levels of apoptosis and no differences 
in the proportions of TUNEL positive cells (a marker of 
apoptosis) were observed between gastrointestinal crypts 
of γ-irradiated wt versus p21-/- mice [32, 33]. Furthermore 
over-expression or knock-down of p21 failed to impair 
or enhance, respectively, the rate of apoptosis in a range 
of cancer derived cell lines when they were treated with 
the p53-activating compound Nutlin3a (an inhibitor of 
MDM2) [35]. By stalling cell cycle progression at the 
G1-S checkpoint p21 may enhance the survival of only 
certain dividing cells that have sustained DNA damage 
by preventing them from replicating their damaged 
DNA, a potentially catastrophic process that may trigger 
apoptosis or another cell death process. Consistent with 
the notion that p21 may only affect death in dividing 
cells, loss of p21 did not protect quiescent (non-cycling) 
cells from DNA damage induced apoptosis, with wt and 
p21-/- thymocytes (which are all G1 phase in culture) 
undergoing comparable levels of apoptosis in response to 
γ–radiation [32]. 
Additional p53 target genes, induced in response to 
DNA damage, have been implicated in the control of cell 
cycle progression at the G1-S and also other checkpoints. 
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For example, MEFs and intestinal epithelial cells lacking 
the transmembrane tyrosine phosphatase, Ptprv, failed 
to arrest at the G1-S boundary after γ-irradiation [36]. 
GADD45a is induced by p53 in several cell types in 
response to γ- as well as UV-irradiation [37, 38] and 
lymphocytes from Gadd45a-/- mice exhibit defective 
G2-M cell cycle arrest post UV-irradiation or treatment 
with methyl methansulfonate (MMS) [39]. GADD45a 
promotes cell cycle arrest by inducing disassociation 
of cyclin B1/CDK1 complexes, which are essential 
for entry into mitosis [40, 41]. Another p53 target, 
14-3-3-sigma, was shown to regulate G2-M cell cycle 
arrest by sequestering CDK1 in the cytoplasm thereby 
blocking cyclin B1/CDK1 complex formation [42, 
43]. In conclusion, p53-induced expression of target 
genes, such as p21, ptprv, GADD45a and 14-3-3-sigma, 
promotes reversible cell cycle arrest at the G1-S or G2-M 
checkpoints to provide cells that have sustained DNA 
damage time to repair these lesions.
In response to DNA damage cells can also undergo 
irreversible growth arrest, a process called cellular 
senescence. Cells undergoing senescence become 
irreversibly halted in the G1 phase of the cell cycle but 
remain metabolically active [8, 44]. The process of cell 
senescence is accompanied by various morphological 
changes and the acquisition of a characteristic gene 
expression profile, including upregulation of INK4A [45], 
ARF [46, 47], p53 [48], PML [49, 50], PAI-1 [51] and p21 
[52-54]. In non-transformed cells, induction of senescence 
is associated with the cessation of their proliferative 
potential that is characterised and governed by the 
decrease in telomere length during consecutive rounds 
of cell division (a process called replicative senescence) 
[55, 56]. Cellular senescence can also be induced by DNA 
damage or activation of certain oncogenes [45, 57]. A role 
for p53 in the induction of cellular senescence was first 
demonstrated when it was observed that p53 deficient 
MEFs failed to undergo replicative senescence [48, 58, 
59]. Furthermore, it was shown that low dose γ-radiation 
of normal diploid fibroblasts induced a long-term growth 
arrest state resembling senescence that was associated 
with upregulation of p21 [57]. Moreover, doxorubicin 
treatment was found to promote permanent growth arrest 
with acquisition of a “senescence-like phenotype” in 
HCT116 colon cancer cells [60]. Induction of senescence 
in these cells was substantially impaired by the loss of p53 
or its direct target p21 [60]. Finally, it was reported that 
cyclophosphamide treatment promoted sustained growth 
arrest with characteristic features of cellular senescence 
in Myc-driven lymphomas that also over-expressed Bcl-2 
(and were therefore protected from apoptosis) [61]. This 
growth arrest was found to be p53-dependent, as p53-
deficient Eµ-myc tumours over-expressing Bcl-2 failed 
to arrest and progressed rapidly during such treatment 
[61]. Interestingly, there is evidence that different genes 
and processes may be required for replicative versus DNA 
damage-induced cellular senescence, as p21-deficient 
MEFs were only defective in the latter [62]. Accordingly, 
p53 induces expression of not only p21 but also several 
additional target genes that are implicated in the induction 
and/or maintenance of cellular senescence, in particular 
PAI-1 and PML [50, 63, 64].  
Apoptosis
In certain cells, particularly hematopoietic ones and 
intestinal epithelial cells, DNA damage will preferentially 
induce apoptosis, a form of programmed cell suicide 
responsible for the removal of unwanted or damaged 
cells from multi-cellular organisms [65]. Apoptosis 
involves the ordered destruction of damaged cells (in 
the absence of inflammation) and is characterised by 
a range of biochemical and morphological changes, 
such as plasma membrane blebbing, cellular surface 
exposure of phosphatidylserine, nuclear condensation 
and fragmentation, DNA cleavage and phagocytosis of 
dead cells by neighbouring innate immune cells [66-68]. 
Cell demolition in apoptosis is mediated by caspases 
(aspartate-specific cysteine proteases) that cleave 
hundreds of cellular proteins, including vital structural 
components [69, 70].
A role for p53 in apoptosis signalling was first indicated 
in studies that found that enforced expression of wt p53 
induced characteristic features of apoptotic cell death [71-
74]. Importantly, subsequent studies showed that lymphoid 
cells (thymocytes, pre-B cells, mature B cells and T cells) 
from p53-/- mice were profoundly resistant to apoptosis 
triggered by γ-irradiation, treatment with etoposide or 
certain other DNA damage-inducing chemotherapeutic 
drugs, both in vitro and in vivo [75-77].  Further studies 
showed that this effect was not limited to haematopoietic 
cells given that intestinal stem cells lacking p53 also 
exhibited profound resistance to γ-irradiation [78].  This 
p53-mediated apoptosis was recognised to be induced 
via the intrinsic apoptotic pathway since it could be 
inhibited by over-expression of pro-survival Bcl-2 family 
members or loss of pro-apoptotic Bcl-2 family members, 
particularly the combined loss of the multi-BH domain 
pro-apoptotic Bak and Bax [77, 79-82]. 
The intrinsic (also called “mitochondrial”, “Bcl-2 
regulated” or “stress induced”) apoptotic pathway can be 
activated by developmental cues or diverse cell stressors 
including cytokine deprivation or DNA damage. Life 
versus death decisions in this pathway are controlled 
by the Bcl-2 protein family, which can be divided into 
three functional sub-groups: the pro-survival Bcl-2 family 
members (Bcl-2, Bcl-XL, Bcl-W, Mcl-1 and A1), the pro-
apoptotic BH3-only proteins (Bad, Bid, Bik, Bim, Bmf, 
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Hrk, Puma and Noxa) and the multi-BH domain pro-
apoptotic Bcl-2 family members (Bak, Bax and possibly 
Bok) [83, 84]. Apoptotic stimuli cause transcriptional, 
post-transcriptional and/or post-translational activation 
of the pro-apoptotic BH3-only proteins. They bind to the 
pro-survival Bcl-2 family members, thereby unleashing 
and activating Bax/Bak, but some BH3-only proteins 
(e.g. Bim, Bid) are also thought to directly activate Bax 
and Bak [85-88]. Activated Bax and Bak form homo-
oligomers that trigger mitochondrial outer membrane 
permeabilisation (MOMP) by a mechanism that remains 
poorly understood. MOMP constitutes the “point of no 
return” in apoptosis signalling and results in release of 
apoptogenic factors, such as cytochrome c and Smac/
DIABLO. This unleashes the cascade of caspase 
(aspartate-specific cysteine protease) activation that 
causes cleavage of hundreds of cellular proteins, thereby 
precipitating cellular demolition [67]. 
A direct link between p53 and the intrinsic apoptotic 
pathways was identified when it was found that the pro-
apoptotic Bcl-2 family members Puma, Noxa and Bax 
are direct transcriptional targets of p53. The puma gene 
has a conserved p53 binding site (consensus sequence) 
within its first intron, and mutation of this site was 
shown to abrogate p53-dependent expression of Puma 
[89-91]. Studies with gene-targeted mice revealed that 
loss of Puma rendered thymocytes and many other cell 
types profoundly resistant to a range of p53-dependent 
apoptotic stimuli, including γ-irradiation and treatment 
with etoposide [92-95]. Interestingly, loss of Puma 
also rendered lymphoid cells (and several other cell 
types) resistant to certain death stimuli (e.g. cytokine 
deprivation, glucocorticoids, phorbol ester) [92-94] that 
activate the intrinsic apoptotic pathway [79] in a p53-
independent manner [77].  
Noxa, another BH3-only protein, is also a direct p53 
target [96]. In response to γ-irradiation, thymocytes were 
found to induce Noxa expression in a p53-dependent 
manner [96] and siRNA-mediated knock-down of 
Noxa inhibited γ-irradiation induced apoptosis in E1A-
transformed MEFs [97]. Experiments with gene-targeted 
mice showed that MEFs lacking Noxa were resistant to 
etoposide [93, 98] and UV-irradiation [99]. Interestingly 
however no protection against apoptosis induced by 
DNA damage was observed in lymphoid cells lacking 
Noxa [93]. These results suggest that Puma and Noxa 
may have functions in apoptosis that are cell type specific 
and/or specific to distinct forms of DNA damage. Studies 
with mice lacking both Puma and Noxa revealed that 
these two BH3-only proteins have overlapping functions 
in DNA damage-induced, p53-mediated apoptosis with 
puma-/-noxa-/- thymocytes exhibiting protection from 
γ-irradiation in vivo comparable to p53-/- cells and more 
extensive than that of their puma-/- counterparts [100]. 
Collectively, these results demonstrate that Puma and 
Noxa account for all of the pro-apoptotic activity of p53 
that is triggered by DNA damage. Puma is the major 
effector of p53-mediated apoptosis, whereas Noxa plays 
a more ancillary role. This is consistent with the finding 
that Puma can bind with high affinity and therefore 
neutralise all pro-survival Bcl-2 family members, 
whereas Noxa interacts only with Mcl-1 and A1 [88, 101, 
102]. Another reason why Puma may be a more potent 
killer than Noxa is provided by several studies, which 
showed that only the former is able to bind to and directly 
activate Bax [86, 87, 103, 104].
So, what are the roles of other p53 targets that have 
been implicated as effectors of apoptosis? In the case of 
PERP, PIG3 and certain others [105-107], there are so 
far no data from gene-targeted mice to inform on their 
functions. However, given that combined loss of Puma 
and Noxa renders many cell types as resistant to DNA 
damage induced apoptosis as loss of p53, we predict that 
they have no essential function in p53-mediated apoptosis, 
but may act in other processes activated by p53. 
Several reports have indicated that p53, activated by 
DNA damage, kills cells through stimulation of the “death 
receptor” (also called “extrinsic”) apoptotic pathway. In 
this pathway (which operates largely in parallel to the 
“intrinsic apoptotic” pathway [108]) members of the 
tumour necrosis factor receptor (TNF-R) family with a 
“death domain” initiate apoptosis through FADD/TRADD 
adaptor protein-mediated caspase-8 activation [109]. 
The death receptor genes, Fas, DR4 and DR5, and some 
other genes implicated in the “death receptor” apoptotic 
pathway were reported to be transcriptionally upregulated 
by p53 [110-118]. However, an essential role for “death 
receptor”-induced apoptosis in p53-mediated cell killing 
has been convincingly dismissed by several studies. For 
example, thymocytes and other haematopoietic cell types 
from mice deficient for Fas or Fas ligand (lpr and gld mice, 
respectively) die normally in response to γ-irradiation, 
while, conversely, p53-/- thymocytes and hepatocytes are 
normally sensitive to Fas-induced killing [108, 119-121]. 
Moreover, cells from mice lacking caspase-8 or FADD, 
which are indispensable for apoptosis induced by all 
“death receptors”, are killed normally when exposed to 
p53-dependent apoptotic stimuli, such as γ-irradiation 
and etoposide [119, 120, 122-127]. Perhaps p53-mediated 
transcriptional induction of “death receptors” serves 
to sensitise cells that have sustained DNA damage or 
hypoxia to TNF, Fas ligand and related death ligands in 
order to orchestrate appropriate overall tissue responses 
to these stress conditions. 
Several studies have indicated that p53 may trigger 
apoptosis via a non-transcriptional mechanism. It was 
reported that in response to γ-irradiation and certain 
other stresses, p53 can shuttle to the outer mitochondrial 
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membrane where it directly interacts with members of 
the Bcl-2 protein family to cause MOMP and consequent 
activation of the caspase cascade. Curiously, p53 was 
shown to bind to anti-apoptotic Bcl-XL as well as pro-
apoptotic Bax and Bak to facilitate MOMP [128-132]. 
The physiological relevance of this proposed process 
remains uncertain. Notably, early work has shown that 
γ-irradiation-induced apoptosis (which depends on p53, 
see above) requires de novo RNA synthesis, as treatment 
of cells with the RNA synthesis inhibitor, 5,6-dichloro-1-
beta-d-ribofuranosylbenzimidazole, promoted complete 
resistance to apoptosis (evidenced by absence of DNA 
fragmentation) [133]. Supporting this idea, several 
groups utilising knock-in mutant strains of mice bearing 
mutations that impair p53’s transactivation function 
(p53Gln25Ser26, p53QS and p5325,26,53,54), have shown that 
cells from these animals are as resistant to p53 dependent 
apoptotic stimuli (e.g. γ- or UV-irradiation) as cells that 
lack p53 completely (i.e. cells from p53-/- mice) [134-
136]. Based on these results and the aforementioned 
findings that combined loss of the pro-apoptotic BH3-only 
proteins Puma and Noxa renders cells as resistant to p53-
mediated apoptosis as loss of p53 itself [100], we believe 
that the proposed post-translational processes have little 
or no role in p53-induced apoptosis under physiological 
conditions.  
In conclusion, in response to DNA damage and 
certain other stress conditions (e.g. hypoxia, ROS) the 
tumour suppressor p53 is activated through complex 
post-translational mechanisms and then transcriptionally 
upregulates target genes, which then mediate cellular 
responses, including cell cycle arrest, apoptosis and 
coordination of DNA repair. 
However, while we have a strong understanding of how 
these effector processes are orchestrated, questions remain 
as to how cell fate is determined after p53 activation, 
namely what determines whether in response to DNA 
damage a cell will undergo growth arrest and continue to 
survive or die? The choice between life and death is likely 
to be modulated by a wide range of factors, including 
the type and strength of the stress applied (although to 
date this has been only poorly correlated to cellular fate), 
differences in the inducibility of initiators of apoptosis 
or cell senescence, influence of other (p53-independent) 
signalling pathways that are activated, differences in the 
basal expression of pro-survival proteins and perhaps also 
factors that function downstream to limit activity of the 
effector pathways, such as inhibition of Puma induction 
by Slug [137] or inhibition of the mTOR pathway by p53. 
Gaining a fuller understanding of the mechanisms that 
control such choices of cell fate could provide critical 
information for the future development of anti-cancer 
therapeutics that trigger these processes more selectively 
(e.g. to favour cell killing over cell growth arrest). 
The role of p53 in tumour suppression
Although originally identified as a proto-oncogene, it 
was soon revealed that p53 exhibited tumour suppressive 
actions. In particular, p53 was shown to inhibit E1A and 
Ras-induced transformation of rat fibroblasts [138]. This 
finding was strengthened by the discovery that the p53 
gene was the most common target for genetic alterations 
in cancer, with ~50% of human cancers bearing mutations 
in this tumour suppressor gene. Importantly, many of the 
remainder harbour mutations or epigenetic changes that 
impair activation of p53 or some of its effector functions 
[1, 139, 140]. In humans, germline heterozygous loss-
of-function mutations in p53 cause familial Li-Fraumeni 
syndrome, in which affected individuals are highly 
predisposed to developing various types of cancers (e.g. 
breast cancer, sarcoma and lymphoid malignancies) often 
at a young age [141-143]. Accordingly, mice lacking p53 
[144, 145] or bearing loss of function point mutations in 
p53, (corresponding to amino acid residues in p53 that are 
altered in Li Fraumeni syndrome patients or in sporadic 
human cancers [146]), develop thymic lymphoma or 
sarcoma with 100% incidence between 150-250 days of 
age.
While the function of p53 in mediating cellular 
responses after acute and extensive DNA damage (e.g. in 
response to γ-irradiation or treatment with etoposide) is 
firmly established, the manner in which p53 suppresses 
the development of cancer is less well understood. 
Stabilisation and activation of p53 is known to occur in 
response to expression of certain onco-proteins, such 
as c-Myc or mutant Ras, which trigger transcription 
of the tumour suppressors p14ARF (humans) or p19ARF 
(mouse) [147]. p14/p19ARF functions to antagonise 
the p53-MDM2 interaction, thereby facilitating p53 
accumulation, transcriptional activity and hence effector 
pathway activation [148, 149, 150]. Genomic instability 
is a hallmark of cancer, although whether this follows 
or precedes transformation is not always clear, and so it 
has been suggested that tumour suppression by p53 may 
also be activated through the DNA damage response 
pathway. Studies on human pre-cancerous lesions (e.g. 
non-small cell lung carcinoma, urinary bladder cancer, 
colorectal carcinoma, breast cancer, melanoma) have 
shown that they exhibit hallmarks associated with DNA 
damage pathway activation, including phosphorylation of 
the kinases ATM and Chk2, phosphorylation of histone 
H2AX and p53 accumulation [151, 152]. Interestingly, 
progression to malignant carcinoma (e.g. in non-
small cell lung carcinoma and urinary bladder cancer) 
correlated with frequent mutation or loss of p53 [151, 
152]. Over-expression of oncogenes that deregulate DNA 
replication, such as cyclin E, Cdc25A, E2F1, in U2OS 
osteosarcoma cells was shown to promote DNA damage 
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response activation (evidenced by p53 and γH2AX 
phosphorylation) suggesting that cross-talk must exist 
between oncogene and DNA damage-induced pathways 
for p53 activation [151, 152].
Given the critical roles of apoptosis, G1-S boundary 
cell cycle arrest and senescence in the p53-regulated 
responses to acute DNA damage in non-transformed 
cells, it has been widely proposed that these same 
processes must also be essential for p53-mediated tumour 
suppression [26, 140, 153]. According to this hypothesis, 
activation of oncogenes (e.g. deregulated expression of 
c-Myc) will cause stabilisation of p53 via ARF-mediated 
inhibition of MDM2 whereas DNA damage, including 
that associated with early oncogenic events (e.g. DNA 
breaks in chromosomal translocations), will cause p53 
activation via stimulation of the ATM/Chk2 kinases. Such 
activation of p53 in nascent neoplastic cells undergoing 
transformation would result in activation of apoptosis, cell 
cycle arrest or cellular senescence, thereby suppressing 
further progression towards malignant disease.  
Figure 1. p53-mediated tumour suppression. The transcription factor p53 imposes a critical barrier against tumourigenesis. 
Almost all human cancers bear genetic alterations that either, directly or indirectly, render p53 non-functional and mice 
lacking p53 are prone to spontaneous tumour formation. The activity of p53 can be stimulated by the activation of certain 
oncogenes, such as deregulated expression of c-Myc or mutant Ras. This oncogenic stress promotes transcription of ARF, 
which then induces p53 stabilisation and accumulation by antagonising the p53-MDM2 interaction. Crosstalk between 
DNA damage-activated and oncogene-induced p53 stabilisation can occur when hyper-proliferation-induced replicative 
stress promotes DNA damage and hence activation of the ATM and ATR kinases. Phosphorylation of p53 and MDM2 by 
ATM/ATR inhibits p53 degradation by interfering with the p53-MDM2 interaction. Stabilised p53 undergoes further post-
translational modifications, such as acetylation and neddylation, to become transcriptionally active. Binding as a homo-
tetramer to specific DNA sequences, p53 mediates induction (and for some targets repression) of a wide range of specific 
target genes, which orchestrate activation of distinct effector processes. However, while apoptosis, cell cycle arrest and 
cellular senescence are critical effector processes induced by p53 in response to acute DNA damage, several studies have 
shown that these processes are largely dispensable for p53-mediated suppression of spontaneous tumour development. 
Instead the ability of p53 to modulate under-appreciated processes, such as DNA repair or control of metabolism, or 
perhaps control of presently unknown processes may be critical for p53-mediated tumour suppression.
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Interesting insight into the impact of restoration of 
p53 function in established malignant tumours that had 
developed as a result of loss or mutation of p53 came from 
studies of Gerard Evan and colleagues. They generated p53 
knock-in mice in which the coding sequences of wt Trp53 
were fused to the coding region of a tamoxifen-sensitive 
version of the oestrogen oestrogen receptor (p53ERTAM 
mice). Expression of p53 in these mice could therefore 
be switched on or off in vivo by the administration of 
4-hydroxy-tamoxifen (4-OHT) [154]. These mice were 
inter-crossed with the lymphoma-prone Eμ-myc transgenic 
mouse model, in which MYC expression is subjugated 
to the Ig heavy chain gene enhancer [155]. This model 
mimics the t[8;14] c-Myc/IgH chromosomal translocation 
that causes Burkitt’s lymphoma in humans. The resulting 
Eµ-myc;p53TAM/+ mice all developed lymphomas that 
showed deletion or loss of function mutations of the wt 
p53 allele [156]. These lymphomas were transplanted into 
recipients to investigate the effects of p53 restoration by 
addition of 4-OHT. Interestingly, even relatively short-
term reactivation of p53 allowed enhanced survival 
of lymphoma-bearing mice. Lymphomas analysed 6 h 
after 4-OHT treatment exhibited markers of apoptosis 
(e.g. increased TUNEL staining, Annexin-V+/Propidium 
iodide+ and sub-G1 cells) [156]. These results suggest 
that restoration of wt p53 function suppresses sustained 
expansion of tumours (at least in the context of Myc-driven 
lymphoma) primarily through induction of apoptosis. 
The importance for apoptosis in p53-mediated (and p53-
independent) suppression of lymphoma development 
in Eµ-myc mice was further demonstrated when it was 
shown that over-expression of Bcl-2 [157] or loss of the 
pro-apoptotic BH3-only proteins Puma and Noxa [158, 
159] (direct p53 targets and essential effectors of p53-
mediated apoptosis) and also loss of the BH3-only protein 
Bim [160] (not a p53 target) substantially accelerated 
lymphomagenesis in Eµ-myc mice.
In another study, Jacks and colleagues [161] 
developed knock-in mice in which expression of the 
endogenous p53 allele was placed under the control of 
a transcription-translation stop cassette flanked by LoxP 
sites. These so-called p53LSL mice were inter-crossed 
with Rosa26CreER mice, which express a tamoxifen 
regulated Cre recombinase in all cell types. The resulting 
p53LSL;CreERT2 mice are p53-deficient in the absence 
of tamoxifen. Accordingly, similar to the p53-/- mice, 
the p53LSL;CreERT2 mice succumbed to spontaneously 
forming thymic lymphomas and (more rarely) sarcomas 
between 120-250 days of age. Addition of tamoxifen 
to such tumour burdened animals promoted activation 
of the CreERT2 recombinase, leading to excision of the 
transcription stop elements at LoxP sites with consequent 
expression of endogenous p53 protein in the tumour (and 
all other) cells [161]. This restoration of p53 resulted in 
the regression of both thymic lymphomas and sarcomas. 
However, while thymic lymphomas displayed widespread 
apoptosis in response to p53 restoration, surprisingly, 
sarcomas regressed in the absence of overwhelming 
apoptosis [161]. Instead, regressing sarcomas exhibited 
markers of senescence, such as β-galactosidase staining 
as well as expression of p15-Ink4b, p16-Ink4a, DcR2 and 
Dec-1 [161]. These observations suggest that the effector 
processes that p53 utilises for tumour growth suppression 
(in the context of established tumours) can vary in a 
cancer type-specific manner. Interestingly, since tumours 
were found to express high levels of the p53 activator 
p19ARF (a potent inhibitor of MDM2-mediated p53 
degradation) and since restoration of p53 in normal tissues 
did not provoke widespread apoptosis or senescence, 
it was suggested that p19ARF (probably induced by the 
oncogenic lesions) was critical to prime tumour cells to 
respond to p53 restoration [161]. Further support for the 
notion that cellular senescence can play an important 
role in p53-mediated suppression of the expansion of 
malignant tumours came from a study performed by 
Lowe and colleagues. They explored the effects of p53 
restoration in a mutant HRasV12-driven murine model 
of liver carcinoma, in which expression of p53 was 
reversibly knocked down using RNA interference [162]. 
As in the study from Tyler Jacks’ group, restoration of 
p53 expression promoted regression of these carcinomas 
in mice in the absence of widespread apoptosis; instead 
regressing carcinomas exhibited markers of decreased 
proliferation and increased senescence [162]. 
These studies provide evidence that apoptosis and/or 
senescence play a critical role in p53-mediated regression 
of established tumours, and were widely thought to provide 
insight into the mechanism by which p53 suppresses the 
initiation of tumour formation. Unexpectedly, however, 
mice lacking single or multiple target genes that are 
essential for p53-mediated induction of apoptosis, cell 
cycle arrest or senescence, such as p21-/-, puma-/-, noxa-
/- and puma-/-noxa-/- mice, do not develop tumours (unlike 
the p53-deficient or p53 mutant mice) [32, 92-94, 98, 
163]. Hence these studies, and several additional ones, 
challenge the essential nature of these three cellular 
processes for p53-mediated tumour suppression. 
Evans and colleagues, utilising the aforementioned 
p53ERTAM knock-in mice probed the requirement for the 
acute DNA damage response triggered by p53 in the 
suppression of tumour development [164]. In the absence 
of 4-OHT, p53ERTAM mice are functionally p53-deficient 
and rapidly succumb to thymic lymphoma after exposure 
to low dose (2.5 Gy) γ-irradiation [164]. Cohorts of 
p53ERTAM mice were either treated with 4-OHT 6 days 
prior to γ-irradiation (“concurrent restoration of p53 
function”) or eight days after γ-irradiation (“delayed 
restoration”), a time point when the bulk of the acute 
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p53-mediated response, including large scale apoptosis 
of thymocytes, had been resolved [164]. Surprisingly, 
while “delayed restoration” of p53 promoted a significant 
(albeit relatively small) increase in tumour-free survival, 
“concurrent restoration” of p53 provided no survival 
advantage when compared to control irradiated mice 
(“no restoration of p53”) [164]. Further studies using 
this mouse model revealed that the survival advantage 
observed in the “delayed restoration” cohort was entirely 
dependent on the expression of p19ARF, which functions 
to stabilise p53 in response to oncogenic stress. This was 
based on the observation that p53ERTAM mice lacking 
p19ARF did not exhibit enhanced survival post “delayed 
restoration” of p53. Taken together, these results suggest 
that the acute response to DNA damage and the pathology 
associated with widespread p53-activation, including 
widespread apoptosis of lymphoid cells, is dispensable 
for p53-mediated tumour suppression [164]. Moreover, 
the requirement for p19ARF for enhanced lymphoma-
free survival suggested that tumour suppression, at least 
within this context, involves p19ARF-mediated activation 
of p53 in rare clones of cells with activated oncogenes 
[164]. While this study constituted a considerable 
advance in understanding of how p53 suppresses tumour 
development, there is one caveat to this work. Mice 
homozygous for the p53ERTAM allele are not functionally 
p53-null, as demonstrated by the failure to rescue the 
embryonic lethality induced by MDM2-deletion [165]. 
Therefore, residual expression of p53 over time could be 
sufficient to kill nascent neoplastic cells accounting for the 
observed survival advantage of these mice. An essential 
role for apoptosis in p53-mediated tumour suppression 
was further questioned when it was reported that mice 
deficient for endogenous (mouse) p53 but carrying a 
human p53 transgene, (p53SWAP mice), were protected 
from rapid tumour development, although their cells were 
unable to undergo p53-mediated apoptosis in response to 
DNA damage [166].
In order to dissect the specific requirements for the 
different transactivation domains in p53 for tumour 
suppression, Attardi and colleagues generated a panel 
of p53 conditional knock-in mice bearing mutations in 
specific residues within these regions [167]. Three mutants 
bearing alterations in either the first (L25Q, W26S: p5325,26 
or p53QS [168]), second (F53Q, F54S: p5353,54) or both 
(L25Q, W26S, F53Q, F54S: p5325,26,53,54) transactivation 
domains of p53 were utilised in this study, with 
regulatable expression of mutant p53 proteins facilitated 
by the introduction of a LoxP-Stop-LoxP-cassette within 
the first intron of the p53 constructs. Microarray analysis 
on mutant HrasV12-transformed MEFs (transduced 
with a Cre recombinase) revealed that in response to 
DNA damage, mutation of both transactivation domains 
produced a “transactivation dead” phenotype, with similar 
gene expression profiles observed between p53-/- and 
p5325,26,53,54 homozygous mutant cells [167]. Conversely, 
mutation of the second transactivation domain alone 
appeared to have minimal impact on the transcription of the 
bulk of the p53-dependent target genes, with HRasV12-
transformed MEFs from p5353,54 mice exhibiting a similar 
expression profile after DNA damage as those from wt 
(p53+/+) cells. In contrast, mice with mutations in the 
first transactivation domain (p5325,26) displayed impaired 
transcriptional induction of a large subset of p53 target 
genes after DNA damage, interestingly including the 
canonical targets p21, Puma and Noxa [167]. As a result 
of impaired induction of these critical effector genes 
diverse cells from these mice were markedly resistant 
to DNA damage-induced cell cycle arrest and apoptosis 
[167]. Remarkably, despite impaired induction of these 
critical effector processes p5325,26 homozygous mutant 
animals, in contrast to p53-deficient mice, did not exhibit 
accelerated tumour formation in a mutant Ras-driven 
transgenic model of non small cell lung cancer (NSCLC) 
with tumour burden observed comparable to wt (p53+/+) 
controls [167]. Likewise, tumourigenesis induced by 
several other oncogenic drivers, such as induction of 
medulloblastoma caused by loss of one allele of Ptch, 
was considerably reduced in p5325,26 homozygous mutant 
mice compared to p53-/- animals [169]. Further analysis 
of the p5325,26 homozygous mutant mice indicated that 
in addition to retaining the ability to suppress tumour 
formation their cells remained able to efficiently undergo 
cellular senescence despite impaired induction of some 
(i.e. p21 and PAI-1) but not all (i.e. PML) p53 target genes 
implicated in this process [167]. Accordingly, the authors 
proposed that cellular senescence (triggered by currently 
“under-appreciated” p53 target genes) may be critical 
for the tumour suppressive action of p53 [167]. In order 
to identify novel target genes involved in p53-mediated 
tumour suppression, Attardi and colleagues utilised 
microarray analysis to identify ~130 p53-regulated genes 
that upon DNA damage were differentially expressed in 
the p5325,26 homozygous mutant cells compared to their 
control (p53-/-) counterparts. Further filtering of these 
results for genes known to be down-regulated in a variety 
of human and mouse cancers, resulted in a list of 14 
candidate genes [167]. Of these candidates, some have 
been implicated in the repair of DNA damage (Ercc5, 
Mgmt, Polk), cytoskeletal function (Arap2, Crip2, Def6, 
Kank3), cell signalling (Abhd4, Phlda3, Rgs12) as well 
a range of other processes (Sidt2, Ttc28, Ndrg4, Ctsf) 
[167]. Knock-down of several of these target genes in 
HRasV12-transformed MEFs accelerated tumour growth 
in vivo, similar in extent to that afforded by knock-down 
of p53 [167]. These p53 target genes should therefore be 
considered as prime candidates for p53-mediated tumour 
suppression and it will be important to determine in which 
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cellular pathways they act. 
Data from another p53 mutant knock-in mouse strain 
however appears to rule out a critical role for cellular 
senescence in p53-mediated tumour suppression. In 
order to define the role for acetylation in modulating 
p53 function, Gu and colleagues generated a p53 knock-
in mouse strain bearing mutations in three conserved 
residues within the DNA binding domain of p53 (K117R, 
K161R and K162R: p533KR mice) that are acetylated 
in response to DNA damage [170]. Acetylation of the 
equivalent residues in human p53 has been shown to play 
a critical role in controlling promoter-specific activation 
of p53 target genes and hence activation of the respective 
effector responses after cellular stress [8, 171]. In particular 
acetylation of K120 in human (K117 in mouse) p53 has 
been shown to be required for the induction of apoptosis, 
whereas loss of acetylation at K120 and K164 (K117 and 
K161 in mouse) was reported to abolish the ability of 
p53 to induce both apoptosis and cell cycle arrest [172]. 
Consistent with findings on human p53, cells from the 
p533KR/3KR mutant mice were unable to undergo apoptosis 
or cell cycle arrest in response to DNA damage. These 
defects were shown to result from impaired transcriptional 
induction of p21, Puma and Noxa. Moreover, induction 
of several other classical p53 target genes was also 
impaired in cells from the p533KR/3KR mutant mice, but they 
retained the ability to induce a small subset of p53 target 
genes, including MDM2 and TIGAR [170]. Interestingly, 
fibroblasts from the p533KR/3KR mutant mice also displayed 
impaired induction of replicative senescence. This defect 
was attributed to abnormally diminished induction of the 
p53 target genes p21, PML and PAI-1 [170]. Remarkably, 
despite profound impairment in the induction of apoptosis, 
cell cycle arrest and senescence, unlike p53-/- mice, the 
p533KR/3KR mutant mice were not tumour-prone, with only 
a low incidence (3/27) of late onset tumours observed 
[170]. Gene expression analysis showed that expression 
of the p53 target genes TIGAR and GLS2, which have been 
implicated in the control of metabolism [173], could still 
be induced efficiently in cells from the p533KR/3KR mutant 
mice. Furthermore, in contrast to p53-/- MEFs, which 
exhibited elevated rates of glucose uptake, glycolysis 
and ROS production under normal culture conditions, 
MEFs from p533KR/3KR mutant mice behaved like wt cells 
[170]. Collectively, these findings prompted the authors 
to suggest that regulation of metabolism but not induction 
of apoptosis, cell cycle arrest or cellular senescence is 
critical for p53-mediated tumour suppression. 
Although these studies constitute a substantial 
advance in our knowledge of how p53 mediates tumour 
suppression, an important caveat of the studies of both 
of the aforementioned p53 mutant mouse strains is that 
the expression of the critical effectors of apoptosis, 
cell cycle arrest and senescence (i.e. Puma and Noxa 
as well as p21, respectively) was only reduced but not 
abrogated. It therefore remained possible that residual 
p53-mediated expression of these target genes might be 
sufficient to suppress tumour development (although this 
was not sufficient to induce apoptosis, cell cycle arrest 
and senescence in response to acute DNA damage). In 
order to resolve this issue, we have recently generated 
mice that lack all of the critical effectors of p53-mediated 
apoptosis (Puma and Noxa) and G1-S cell cycle arrest 
as well as cellular senescence (p21) and investigated 
their predisposition to cancer. Consistent with previous 
studies of mice lacking Puma [93] or Puma and Noxa 
[100], thymocytes from p21-/-puma-/-noxa-/- were 
profoundly resistant to DNA damage-induced, p53-
mediated apoptosis, in fact to an extent comparable 
to p53-/- cells. Furthermore activated, proliferating T 
lymphoblasts derived from p21-/-puma-/-noxa-/- mice failed 
to undergo G1-S boundary cell cycle arrest in response to 
γ-irradiation. Interestingly, while dermal fibroblasts from 
p21-/-puma-/-noxa-/- mice were profoundly impaired in the 
induction of DNA damage-induced cellular senescence 
when compared to fibroblasts from wt mice (>80% in 
wt versus ~30% in p21-/-puma-/-noxa-/- fibroblasts) they 
were less resistant compared to the     p53-/- fibroblasts 
[174]. This finding can be explained as while p21 is 
important for induction of cellular senescence, it is not 
the sole p53-activated effector of this process with genes 
such as PML and PAI-1 also being implicated [49,63, 64]. 
Remarkably, although induction of apoptosis and G1-S 
cell cycle arrest were completely abrogated and cellular 
senescence substantially impaired in these mice, none of 
the p21-/-puma-/-noxa-/- mice developed tumours (or any 
other disease) within the 500-day observation period. 
In contrast, all (n=125) p53-/- mice had succumbed to 
lymphoma or more rarely, sarcoma, between 120 to 250 
days of age [174]. These results demonstrate beyond 
doubt that suppression of spontaneous tumourigenesis by 
p53 does not require p21-mediated cell cycle arrest and 
senescence (although not ruling out senescence induced 
by other effectors) as well as Puma/Noxa-mediated 
apoptosis. 
These data do not, however, exclude that p53-induced 
apoptosis, cell cycle arrest and/or senescence may 
contribute to p53-mediated tumour suppression in the 
context of certain oncogenic driver mutations. Indeed, as 
discussed earlier, the loss of Puma or the combined loss 
of Puma and Noxa accelerated Myc-induced lymphoma 
development [158, 159]. It is, however, important to 
note that the loss of both Puma and Noxa accelerated 
lymphoma development in Eµ-myc mice to a considerably 
lesser extent than loss of even a single allele of p53 
(median survival Eµ-myc;p53+/-: <40 days versus Eμ-
myc;puma-/-;noxa-/-: 66 days). This finding demonstrates 
that even in this context where induction of apoptosis (via 
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Puma/Noxa) does contribute to p53-mediated tumour 
suppression, additional processes activated by p53 must 
be even more critical. Collectively, these studies suggest 
that while apoptosis, cell cycle arrest and senescence 
are required for the p53-activated cellular responses to 
acute DNA damage, these processes are not essential 
for p53-mediated suppression of tumour development. 
It therefore appears that p53 functions as a multi-faceted 
transcription factor that utilises distinct transcriptional 
programs to respond to different cellular stresses, i.e. 
utilising primarily apoptosis, cell arrest and senescence to 
respond to acute DNA damage but necessitating distinct 
processes for tumour suppression.
So the question arises, which effector processes 
controlled by p53 are critical for tumour suppression? 
As mentioned above, in their studies with the p533KR/3KR 
mice, Gu and colleagues concluded that coordination of 
metabolism might be critical [170]. The role of p53 in the 
control of metabolism and the contribution of this process 
to tumour suppression are fields of increasing interest. 
Under normal conditions where oxygen is not limiting, 
cells primarily derive their ATP from the conversion of 
glucose to pyruvate (glycolysis). Pyruvate is then shunted 
into the TCA cycle leading to the generation of NADH 
intermediates for oxidative phosphorylation (aerobic 
respiration) [175]. In contrast, cancer cells (particularly in 
hypoxic areas of solid tumours) are known to undergo a 
metabolic switch to utilise “aerobic glycolysis” as a primary 
source for ATP, in a process termed the “Warburg effect” 
[175]. In this process, pyruvate is primarily converted into 
lactate and intermediates formed during the TCA cycle 
are redirected to other biochemical processes that aid cell 
proliferation by providing essential metabolites, such 
as acetyl-CoA for fatty acids and ribose for nucleotides 
[175]. Interestingly, p53 was recently shown to be a 
transcriptional activator of genes that regulate metabolism, 
such as GLS2 and TIGAR, which control glycolytic flux 
within cells [173, 176, 177]. Furthermore, p53 was shown 
to directly suppress expression of GLUT1 and GLUT4 
and indirectly suppress GLUT 3, glucose transporters that 
regulate cellular glucose levels [178]. Therefore, loss of 
p53 function would facilitate a metabolic switch to aerobic 
glycolysis thereby promoting increased proliferation and 
survival of tumour cells. Another hallmark of deregulated 
metabolism is the increased production of intracellular 
reactive oxygen species (ROS). This can result in ROS-
induced DNA damage, thereby enhancing the likelihood 
for accrual of DNA mutations that would promote 
neoplastic progression [179]. 
While coordination of metabolism represents a 
credible and interesting possibility to explain how p53 
suppresses tumour formation, other known and possibly 
also some unknown p53 effector processes may be 
equally or even more critical. Interestingly, we found 
that upon γ-irradiation, cells from p53-/- animals (which 
are tumour-prone) displayed impaired induction of genes 
implicated in DNA repair and a trend towards abnormally 
increased persistence of γH2AX foci (a marker of 
detection of double-strand DNA breaks and initiation of 
their repair) [174]. In contrast, cells from p21-/-puma-/-
noxa-/- mice (which are not tumour-prone) behaved like 
wt cells in these respects. Consequently, we hypothesise 
that proper coordination of DNA repair by p53 may be 
critical to suppress tumour development. Known as the 
“guardian of the genome” p53 was initially implicated in 
the coordination of DNA repair via its ability to induce 
cell cycle arrest post DNA damage, a process that would 
allow for sufficient time for DNA damage to be properly 
repaired [37, 180]. The connection between p53 and DNA 
repair has been substantially affirmed with the finding that 
p53 can transcriptionally upregulate a number of genes 
that have critical roles in DNA damage recognition and 
repair, including p53R2, DDB2, DDIT4, ERCC5, FANCC, 
GADD45A, MGMT, MSH2, POLK, XPC [37, 167, 181-
187]. Moreover, p53 has also been suggested to facilitate 
DNA repair by directly interacting with certain DNA 
repair factors at sites of DNA lesions [188]. While the 
loss of individual p53 target genes implicated in DNA 
repair fails to reproduce the marked spontaneous tumour 
predisposition of p53-deficient mice, loss of several of these 
targets have been shown to accelerate tumourigenesis in 
radiation-induced models of carcinogenesis. For example, 
XPC-deficient mice are prone to UVB-induced skin 
cancer [189] and GADD45a-deficient mice are prone to 
γ-irradiation-induced carcinogenesis [190]. Importantly, 
mutation or loss of some of these genes in humans are 
linked to disorders in which individuals are prone to 
various forms of cancer. For example, XPC mutations in 
Xeroderma pigmentosum are associated with a high risk 
of skin cancer [191]; MSH2 mutations cause hereditary 
non-polyposis colorectal cancer (HNPCC) [192, 193]; 
and mutations in FANCC lead to Fanconi anaemia, a 
disorder characterised by progressive bone marrow 
failure and marked predisposition to myeloid leukaemia 
and squamous cell carcinoma [194, 195]. Interestingly, 
cells undergoing early stages of neoplastic transformation 
often display signs of DNA damage response signalling, 
including ATM and Chk2 phosphorylation as well as 
p53 accumulation [151, 152]. This indicates that p53-
mediated tumour suppression may involve recognition 
and repair of DNA lesions caused by replicative stress 
in cells undergoing oncogene-driven hyper-proliferation. 
According to this model, activation of p53 would trigger 
repair of such lesions and thereby minimise acquisition 
of cooperating mutations that would otherwise promote 
progression towards a malignant phenotype. 
Another intriguing idea is that p53 may also function 
as a guardian of normal cellular stresses, in addition to 
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its defined roles in responses to acute stresses. In healthy 
cells p53 is constitutively expressed, albeit restrained 
at low levels. Accordingly, constitutive expression of 
p53 would allow for its transient activation in response 
to normal cellular stresses such as, DNA strand breaks 
that occur during replication or transient changes in 
cellular metabolites. Such transient p53 activation would 
be predicted to be insufficient to activate apoptosis or 
cellular senescence, either because these stresses induce 
different overall transcriptional programs or simply due 
to the transient nature of the p53 response in this context 
(e.g. to elicit apoptosis, Puma/Noxa levels must increase 
sufficiently to overcome the protective effects of the pro-
survival Bcl-2 family members present within a given 
cell). Such transient p53 activation, although at low 
levels, might be sufficient to counter early tumourigenic 
events, such as oncogene activation. 
Regardless, it is apparent that much remains unknown 
about how p53 mediates tumour suppression, and so, 
the search for the p53 target genes and the processes 
they regulate that are critical to protect us from 
developing cancer continues. Much work remains to 
validate the function of the newly discovered candidate 
genes implicated as critical for tumour suppression in 
the aforementioned studies (e.g. through use of gene-
targeting strategies on targets identified by Attardi et al 
[167] and Gu et al [170]). Furthermore, there is a need 
to re-examine our current knowledge of p53 target genes 
to ensure it encompasses all actual p53 targets. Finally, 
understanding if (and how) the transcriptional programs 
initiated by p53 differ (perhaps subtly) in response 
to distinct cellular stressors (e.g acute DNA damage 
versus oncogene activation) may provide insight into 
p53’s functions as a tumour suppressor. Understanding 
and harnessing newly implicated effector processes 
could lead to more efficacious anti-cancer treatment 
strategies, for example through development of novel 
cancer therapeutics that reactivate these processes within 
cancer cells or alternatively in pre-neoplastic cells of 
people bearing cancer-predisposing gene mutations. This 
may be pertinent to Li-Fraumeni patients with germline 
mutations in p53 or individuals bearing mutations in 
genes where the resulting tumours exhibit high rates of 
p53 mutation (e.g. women bearing BRCA1/BRCA2 
mutations). Selective activation of effector processes 
critical for tumour suppression may also result in reduced 
treatment side effects. For example, interventions that do 
not elicit widespread apoptosis would minimise lymphoid 
and gastrointestinal tract depletion. 
Conclusions
To conclude, p53 imposes a critical barrier against the 
development of cancer. However, the mechanisms by 
which p53 mediates tumour suppression remain elusive. 
Surprisingly, it appears that suppression of spontaneous 
tumour formation by p53 utilises distinct effector processes 
from those that are critical for the cellular responses to 
acute DNA damage. Experiments utilising p53 mutant 
knock-in mice or gene-targeted knock-out mice lacking 
well-characterised p53 effector genes have demonstrated 
that induction of apoptosis, cell cycle arrest and cellular 
senescence, even in combination, appear largely 
dispensable for the ability of p53 to suppress spontaneous 
tumour development. Instead, p53 must mobilise currently 
underappreciated processes, such as coordination of DNA 
repair, control of metabolic adaptation or perhaps even 
currently unknown processes to suppress cancer formation. 
Defining the effector processes that are critical for p53-
mediated tumour suppression and how the signalling 
pathways responsible for these processes are triggered by 
oncogenic events remain critical goals of future research. 
Detailed understanding of these processes will have great 
potential to aid in the development of novel strategies for 
cancer therapy and possibly even cancer prevention.
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